Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3748/wjg.v12.i4.516 http://scihub22266oqcxt.onion/10.3748/wjg.v12.i4.516 16489662!4066081!16489662     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       World+J+Gastroenterol 2006 ; 12 (4): 516-9 Nephropedia Template TP {{tp|p=16489662|t=2006. Progress in treatment of massive ascites and hepatorenal syndrome |pdf=|usr=}}{{16489662}} gab.com Text Progress in treatment of massive ascites and hepatorenal syndrome JO: World J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=16489662 #FOAvip Massive ascites and hepatorenal syndrome (HRS) are frequent complications of liver cirrhosis. Thus, effective therapy is of great clinical importance. This concise review provides an update of recent advances and new developments. Therapeutic paracentesis can be safely performed even in patients with severe coagulopathy. Selected patients with a refractory or recurrent ascites are good candidates for non-surgical portosystemic shunts (TIPS) and may have a survival benefit and improvement of quality of life. Novel pharmaceutical agents mobilizing free water (aquaretics) are currently under test for the therapeutic potential in patients with ascites. Prophylaxis of hepatorenal syndrome in patients with spontaneous bacterial peritonitis is recommended and should be considered in patients with alcoholic hepatitis. Liver transplantation is the best therapeutic option with long-term survival benefit for patients with HRS. To bridge the time until transplantation, TIPS or Terlipressin and albumin are good options. Albumin dialysis can not be recommended outside prospective trials. Twit Text FOAVip Progress in treatment of massive ascites and hepatorenal syndrome ????World J Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=16489662 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=16489662 #FOAvip English Wikipedia <ref>{{Cite pmid|16489662}}</ref> Progress in treatment of massive ascites and hepatorenal syndrome #MMPMID16489662 Gerbes AL; Gulberg V World J Gastroenterol 2006[Jan]; 12 (4): 516-9 PMID16489662show ga Massive ascites and hepatorenal syndrome (HRS) are frequent complications of liver cirrhosis. Thus, effective therapy is of great clinical importance. This concise review provides an update of recent advances and new developments. Therapeutic paracentesis can be safely performed even in patients with severe coagulopathy. Selected patients with a refractory or recurrent ascites are good candidates for non-surgical portosystemic shunts (TIPS) and may have a survival benefit and improvement of quality of life. Novel pharmaceutical agents mobilizing free water (aquaretics) are currently under test for the therapeutic potential in patients with ascites. Prophylaxis of hepatorenal syndrome in patients with spontaneous bacterial peritonitis is recommended and should be considered in patients with alcoholic hepatitis. Liver transplantation is the best therapeutic option with long-term survival benefit for patients with HRS. To bridge the time until transplantation, TIPS or Terlipressin and albumin are good options. Albumin dialysis can not be recommended outside prospective trials. |Antidiuretic Hormone Receptor Antagonists[MESH] |Ascites/*therapy[MESH] |Body Water/metabolism[MESH] |Dialysis[MESH] |Hepatorenal Syndrome/prevention & control/*therapy[MESH] |Humans[MESH] |Liver Cirrhosis/*complications[MESH]Progress in treatment of massive ascites and hepatorenal syndrome (epmc).pdf DeepDyve Pubget Overpricing